USE OF AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 FOR POPULATION REVACCINATION IN PEOPLE OVER 60 AND/OR WITH CHRONIC DISEASES (VERSIONS) Russian patent published in 2021 - IPC C12N7/00 A61K39/215 A61P31/14 C12N15/62 

FIELD: biotechnology, immunology and virology.

SUBSTANCE: group of invention relates to biotechnology, immunology and virology. Described is the use of an agent containing component 1 which is in form of expression vector based on recombinant strain human adenovirus serotype 26, in which E1 and E3 regions are deleted, and ORF6-Ad26 is replaced by ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or component 2 which is in form of expression vector based on recombinant strain human adenovirus serotype 5, in which E1 and E3 regions are deleted with integrated expression cassette selected from в SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against severe acute respiratory syndrome Sars-CoV-2 in people over 60 and/or with chronic diseases. Also used is an agent containing component 1, which is an agent in form of expression vector based on recombinant strain human adenovirus serotype 26, in which E1 and E3 regions are deleted, and ORF6-Ad26 is replaced by ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and also contains component 2, which is an agent in form of expression vector based on based on recombinant strain simian adenovirus serotype 25, in which E1 and E3 regions are deleted, and ORF6-Ad26 is replaced by ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 or contains only component 2 for induction of specific immunity against severe acute respiratory syndrome Sars-CoV-2 in people over 60 and/or with chronic diseases. Also proposed is an agent containing component 1 which is an agent in form of expression vector based on recombinant strain human simian adenovirus serotype 25, in which E1 and E3 regions are deleted with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 and also contains component 2, which is an agent in form of expression vector based on recombinant strain human adenovirus serotype 5, in which E1 and E3 regions are deleted with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for induction of specific immunity against severe acute respiratory syndrome Sars-CoV-2 in people over 60 and/or with chronic diseases..

EFFECT: invention provides effective induction of specific immunity against severe acute respiratory syndrome Sars-CoV-2 in people over 60 and/or with chronic diseases.

9 cl, 3 dwg, 7 tbl, 13 ex